Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Nefopam hydrochloride 30 mg Film-coated Tablets

Active Ingredient:
nefopam hydrochloride
Glenmark Pharmaceuticals Europe Ltd See contact details
ATC code: 
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 10 Aug 2020
1. Name of the medicinal product

Nefopam hydrochloride 30 mg Film-coated Tablets

2. Qualitative and quantitative composition

Each film-coated tablet contains 30 mg of Nefopam hydrochloride

For the full list of excipients, see section 6.1

3. Pharmaceutical form

Film-coated Tablet

White to off white, round, film-coated biconvex tablets engraved with “ 20” on one side and “ G” on the other side.

4. Clinical particulars
4.1 Therapeutic indications

Nefopam is indicated for the relief of acute and chronic pain, including post-operative pain, dental pain, musculo-skeletal pain, acute traumatic pain and cancer pain.

4.2 Posology and method of administration



Dosage may range from 1 to 3 tablets three times daily depending on response. The recommended starting dosage is 2 tablets three times daily.


Older patients may require reduced dosage due to slower metabolism.

It is strongly recommended that the starting dose does not exceed one tablet three times daily as older people appear more susceptible to, in particular, the CNS side effects of Nefopam and some cases of hallucinations and confusion have been reported in this age group.

Paediatric Population:

The safety and efficacy of Nefopam in children under 12 years has not yet been established. No dosage recommendation can be given for patients under 12 years.

Patients with end stage renal disease might experience increased serum peak concentrations during treatment with nefopam. In order to avoid that, it is recommended the daily dose should be reduced not only for the elderly, but also for patients with terminal renal insufficiency.

Method of administration

Oral use

4.3 Contraindications

Nefopam is contra-indicated in patients with a history of convulsive disorders and should not be given to patients taking mono-amine-oxidase (MAO) inhibitors.

Nefopam is contraindicated in patients with known hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

The side effects of Nefopam may be additive to those of other agents with anticholinergic or sympathomimetic activity. It should not be used in the treatment of myocardial infarction since there is no clinical experience in this indication. Hepatic and renal insufficiency may interfere with the metabolism and excretion of nefopam.

Nefopam should be used with caution in patients with angle closure glaucoma. Cases of nefopam dependence and abuse have been reported with nefopam use.

Nefopam should be used with caution in patients with, or at risk of, urinary retention.

Rarely a temporary, harmless pink discolouration of the urine has occurred.

4.5 Interaction with other medicinal products and other forms of interaction

Caution should be exercised when nefopam is administered concurrently with tricyclic antidepressants.

It should be noted that nefopam may interfere with some screening tests for benzodiazepines and opioids. These tests for benzodiazepines and opioids may give false positive results for patients taking Nefopam.

4.6 Fertility, pregnancy and lactation

There is no evidence as to the drug safety in human pregnancy, nor is the evidence from animal work that it is free from hazard. Avoid in pregnancy unless there is no safer treatment.

4.7 Effects on ability to drive and use machines

Not applicable

4.8 Undesirable effects

Nausea, nervousness, dry mouth and light-headedness, urinary retention, hypotension, syncope, palpitations, gastrointestinal disturbances (including abdominal pain and diarrhoea), dizziness, paraesthesia, convulsions, tremor, confusion, hallucination, angioedema, and allergic reactions may occur. Less frequently, anaphylactic reactions, coma, vomiting, blurred vision, drowsiness, sweating, insomnia, headache and tachycardia have been reported.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme, Website: or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

The clinical pattern of nefopam toxicity in overdose is on the neurological (coma, convulsions, hallucinations and agitation) and cardiovascular systems (tachycardia with a hyperdynamic circulation). Routine supportive measures should be taken and prompt removal of ingested drug by gastric lavage or induced vomiting with syrup of Ipecacuanha should be carried out. Oral administration of activated charcoal may help prevent absorption.

Convulsions and hallucinations should be controlled (eg. With intravenously or rectally administered diazepam). Beta-adrenergic blockers may help control the cardiovascular complications.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Non-opioid analgesics and compound analgesic preparations

ATC code: N02BG06

Nefopam is a potent and rapidly-acting analgesic. It is totally distinct from other centrally-acting analgesics such as morphine, codeine, pentazocine and propoxyphene.

Unlike the narcotic agents, Nefopam has been shown not to cause respiratory depression. There is no evidence from pre-clinical research of habituation occurring with Nefopam.

5.2 Pharmacokinetic properties

Nefopam is absorbed from the gastro-intestinal tract. Peak plasma concentrations occur about 1-3 hours after oral administration. About 73% is bound to plasma proteins. It has an elimination half-life of about 4 hours. It is extensively metabolised and excreted mainly in urine. Less than 5% of a dose is excreted unchanged in the urine. About 8% of a dose is excreted via the faeces.

5.3 Preclinical safety data

Not applicable

6. Pharmaceutical particulars
6.1 List of excipients

Tablet core:

Calcium hydrogen phosphate, dihydrate

Microcrystalline cellulose

Pregelatinised starch

Colloidal anhydrous silica

Magnesium stearate

Film-coating material:

Hydroxypropyl methylcellulose

Polyethylene glycol 6000 & 400

Titanium dioxide E171

6.2 Incompatibilities

Not Applicable

6.3 Shelf life

2 years

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

Tablets are packed in either an Alu-Alu blister pack (consisting of 60µ PVC/50µ Alu/25µ OPA and aluminium foil).

Each pack contains 90 film-coated tablets (9 blisters of 10 film-coated tablets)

6.6 Special precautions for disposal and other handling

No special requirements for disposal.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Glenmark Pharmaceuticals Europe Limited

Laxmi House, 2 B Draycott Avenue

Kenton, Middlesex, HA3 0BU,

United Kingdom

8. Marketing authorisation number(s)

PL 25258/0300

9. Date of first authorisation/renewal of the authorisation


10. Date of revision of the text


Glenmark Pharmaceuticals Europe Ltd
Company image
Building 2, Croxley Park, Watford, WD18 8YA
+44 (0)1923 202 950
+44 (0)1923 251137
Medical Information Direct Line
0800 458 0383
Stock Availability
+44 (0)1923 202 950